TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06277037: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Sponsor: Arbutus Biopharma Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,191,200

Rescue Site Savings

+$1,460,800

Unlock Full NCT06277037 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06277037 Rescue Dossier →